Loading clinical trials...
Loading clinical trials...
Single-dose, Randomized, Two-period, Two-sequence Crossover Study to Evaluate the Bioequivalence of Lepsiramp 0.5mg/ml Oral Suspension (Test) and Fycompa® 0.5mg/ml Oral Suspension (Reference) Under Fasting Conditions
Conditions
Interventions
Lepsiramp, 0.5 Mg/mL Oral Suspension
Fycompa, 0.5 Mg/mL Oral Suspension
Locations
1
Egypt
Advanced Research Center (ARC)
Cairo, Cairo Governorate, Egypt
Start Date
March 7, 2024
Primary Completion Date
July 23, 2024
Completion Date
July 23, 2024
Last Updated
August 20, 2025
NCT06924190
NCT06600282
Lead Sponsor
Aya Mohammed Abdel Magid Abdel Hamid
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions